



# Cytoskeleton-dependent clustering of membrane-bound prion protein on the cell surface

Received for publication, August 21, 2020, and in revised form, January 26, 2021. Published, Papers in Press, February 2, 2021, <https://doi.org/10.1016/j.jbc.2021.100359>

Stefanie Hackl<sup>1</sup>, Xue Wen Ng<sup>2</sup>, Danqin Lu<sup>2,3</sup>, Thorsten Wohland<sup>2</sup>, and Christian F. W. Becker<sup>1,\*</sup>

From the <sup>1</sup>University of Vienna, Faculty of Chemistry, Institute of Biological Chemistry, Vienna, Austria; <sup>2</sup>Departments of Biological Sciences and Chemistry and Centre for Bioimaging Sciences (CBIS), National University of Singapore (NUS), Singapore; and <sup>3</sup>School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China

Edited by Paul Fraser

Prion diseases are a group of neurodegenerative disorders that infect animals and humans with proteinaceous particles called prions. Prions consist of scrapie prion protein (PrP<sup>Sc</sup>), a misfolded version of the cellular prion protein (PrP<sup>C</sup>). During disease progression, PrP<sup>Sc</sup> replicates by interacting with PrP<sup>C</sup> and inducing its conversion to PrP<sup>Sc</sup>. Attachment of PrP<sup>C</sup> to cellular membranes *via* a glycosylphosphatidylinositol (GPI) anchor is critical for the conversion of PrP<sup>C</sup> into PrP<sup>Sc</sup>. However, the mechanisms governing PrP<sup>C</sup> conversion and replication on the membrane remain largely unclear. Here, a site-selectively modified PrP variant equipped with a fluorescent GPI anchor mimic (PrP-GPI) was employed to directly observe PrP at the cellular membrane in neuronal SH-SY5Y cells. PrP-GPI exhibits a cholesterol-dependent membrane accumulation and a cytoskeleton-dependent mobility. More specifically, inhibition of actin polymerization reduced the diffusion of PrP-GPI indicating protein clustering, which resembles the initial step of PrP aggregation and conversion into its pathogenic isoform. An intact actin cytoskeleton might therefore prevent conversion of PrP<sup>C</sup> into PrP<sup>Sc</sup> and offer new therapeutic angles.

Prion diseases or transmissible spongiform encephalopathies (TSEs) are incurable, neurodegenerative disorders (1). The central pathophysiologic event is ascribed to the conformational change of the  $\alpha$ -helical, cellular (PrP<sup>C</sup>) into the toxic,  $\beta$ -sheet-enriched scrapie prion protein (PrP<sup>Sc</sup>) (2, 3). PrP<sup>Sc</sup> can then not only propagate further PrP<sup>C</sup> misfolding but is also capable of infecting other organisms (4). To date, the mechanisms of PrP<sup>C</sup>-PrP<sup>Sc</sup> conversion, PrP<sup>Sc</sup> replication, and the molecular pathways leading to neurodegeneration are largely unknown. Native PrP<sup>C</sup> is tethered *via* its glycosylphosphatidylinositol (GPI) anchor to the outer leaflet of neuronal plasma membranes (5). Several studies ascribe a crucial role in the pathogenesis of prion diseases and PrP<sup>C</sup>-PrP<sup>Sc</sup> conversion to membrane attachment of PrP (6–13), where contact between endogenous PrP<sup>C</sup> and exogenous PrP<sup>Sc</sup> can easily occur and membrane properties can impact protein structure and function.

In this context, deciphering the earliest pathophysiologic events in prion diseases by direct observation of

posttranslationally modified PrP at the cellular membrane, the initial site of prion infection and PrP misfolding is of utmost importance. So far, most studies used recombinant PrP lacking posttranslational modifications as a surrogate (14–18) or heterogeneous protein preparations isolated from mammalian cell lines (14–16). To this end, semisynthesis offers a unique possibility to access homogeneous, membrane-anchored, labeled PrP-GPI (Fig. 1). The semisynthetic approach relies on linking a synthetic membrane anchoring peptide to recombinantly produced PrP- $\alpha$ -thioester by expressed protein ligation (EPL) (17–19). We have previously applied similar strategies to generate a variety of modified PrP variants (20–23). These experiments revealed specific binding of PrP-GPI to membranes, distinct from unmodified PrP, with impact on biochemical and conformational properties of the protein. Critical roles for both the C-terminal and the N-terminal domain of PrP-GPI were found (22). Noteworthy, PrP containing a GPI anchor mimic performed similar as PrP equipped with a native GPI anchor (20, 21). Here, we aim at directly studying the movement of semisynthetic membrane-anchored PrP in its native environment by fluorescence microscopy. This setup allows discerning the effect of membrane properties on PrP mobility and their role in triggering protein misfolding.

## Results

### Semisynthesis of homogeneously Cy5-labeled PrP equipped with a GPI anchor mimic (PrP-GPI)


Extension of our semisynthetic approach toward additional fluorescence labeling with Cy5 produced homogeneously labeled PrP-GPI to directly study the PrP-cellular membrane interaction within living neuronal SH-SY5Y cells (Fig. 1). Expressed protein ligation (EPL) under optimized conditions afforded pure PrP-GPI with a yield of 14% over all steps (ESI), which was folded with 69% yield. CD spectroscopy revealed a predominantly  $\alpha$ -helical fold, in very good agreement with previously reported results (Fig. S1) (22, 24, 25).

### PrP-membrane localization studied by structured illumination microscopy (SIM) imaging

In turn, cell imaging experiments based on superresolution structured illumination microscopy (SR-SIM) combined with

\* For correspondence: Christian F. W. Becker, [christian.becker@univie.ac.at](mailto:christian.becker@univie.ac.at).

## Early steps in prion protein aggregation on the membrane




**Figure 1. Semisynthesis strategy for directly studying the interaction between PrP and the cellular membrane by using Cy5-labeled PrP (aa 23–231) equipped with a GPI anchor mimic (PrP-GPI).** Schematic outline of the primary (top) and the tertiary structure of PrP<sup>C</sup> is based on NMR measurements and residue numbers of human PrP<sup>C</sup> (aa 23–230). The tertiary structure of PrP<sup>C</sup> was taken from the protein data bank (PDB) entry 1QLZ (77).

colocalization analysis were then applied to study the cellular localization of folded Cy5-labeled PrP-GPI. In our experimental setup, superresolution (SR) images of SH-SY5Y cells were acquired with SIM (Fig. 2A).

Prior to fixation, these cells were incubated for 1 h with Cy5-labeled PrP-GPI in the presence of Cellmask (to stain membranes). In order to accelerate the process of PrP-GPI transfer from solution to the cell membrane, the cationic liposome-based transfection agent Pro-Ject was employed (26).

For quantification and statistical interpretation of colocalization between PrP-GPI and the cellular membrane, Pearson's ( $r_p$  or PCC) and Manders' ( $M_1$ ,  $M_2$ ) coefficients (27, 28) were calculated and evaluated with thresholds and significances ( $p$ -values) determined by the Costes' approach (29, 30) (Fig. 2B). Colocalization was proven with Manders' ( $M_1$ ,  $M_2$ ) coefficients close to 1 (Fig. 2B). In addition, a plot of the Van Steensel's cross-correlation function (CCF) (31) was obtained by shifting one of the SIM images relative to the other, which afforded a



**Figure 2. SR images and colocalization analysis of SH-SY5Y cells incubated with the Cy5-labeled PrP-GPI.** *A*, SR images and the corresponding ROIs (regions of interest) used in the colocalization analysis show the CellMask green (left) and Cy5 fluorescence (right) of the membrane and PrP-GPI. *B*, a maximum intensity Z-projection of the Costes' mask (white: colocalization, black: background, red: Cy5 fluorescence, green: CellMask green fluorescence) illustrates the colocalization based on calculated thresholds according to Costes' statistical significance algorithm (29). Based on that, the colocalization was quantified with calculated intensity correlation quotients (ICQ) (64), Pearson's (PCC) and Manders' coefficients ( $M_1$ ,  $M_2$ ) (27, 28), and statistically evaluated with  $p$ -values by Costes' (29). Additional evidence for colocalization was provided by the plot of the Van Steensel's cross-correlation functions (CCFs) (31).

bell-shaped curve with its maxima located at  $\delta x = 0$ , confirming complete colocalization (Fig. 2B). The observed membrane-binding pattern agrees very well with findings reported for other PrP variants carrying a GPI anchor (mimic) and for PrP<sup>C</sup> (20). On the contrary, PrP lacking a GPI anchor was not found to be located at the cellular membrane but occurred as small, bright spots that most likely constitute large PrP aggregates. Noteworthy, the GPI anchor mimic by itself showed a strong interaction with the cell membrane confirming its critical role in localizing PrP-GPI on the membrane (Fig. S2). Taken together, SR microscopy combined with quantitative and statistical colocalization analysis verified native-like membrane localization of our semisynthetic PrP-GPI species on SH-SY5Y cells.

### Impact of PrP-GPI on membrane organization


This was the basis for further studying the relation between PrP-GPI and the highly dynamic and spatially heterogeneous membrane on a molecular level by fluorescence correlation spectroscopy (FCS). Assessing diverse molecular dynamics in live specimen is a challenge well met by FCS. By measuring dynamic processes such as diffusion and interactions within typical timescales of micro- to milliseconds based on fluctuations of the fluorescence signal, FCS provides a quantitative approach to observe such mechanisms at the molecular level (32). For assessing PrP-membrane interactions, the membrane accumulation and mobility of Cy5-labeled PrP-GPI at the plasma membrane of SH-SY5Y cells were analyzed together with established membrane probes that are linked to different patterns of membrane organization. Treatments with methyl- $\beta$ -cyclodextrin (m $\beta$ CD), a cholesterol-depleting agent that

changes membrane composition, and addition of latrunculin A (LatA), an actin polymerization inhibitor (33–36), allow investigating the mobility of PrP-GPI within the membrane and can provide novel links to its function (37).

To assess the role of cholesterol-dependent membrane domains on PrP-GPI membrane localization, SH-SY5Y cells transiently transfected with green fluorescent protein carrying a C-terminal glycosylphosphatidylinositol anchor (GFP-GPI AP) that acts as a cholesterol-dependent membrane domain marker were treated with m $\beta$ CD, a cholesterol-depleting agent (38–40). The role of these cholesterol-rich domains in PrP-GPI plasma membrane anchoring was visualized by confocal imaging. Quantification was based on colocalization analysis of nontreated compared with m $\beta$ CD pretreated GFP-GPI AP transfected SH-SY5Y cells incubated with Cy5-labeled PrP-GPI. Over a time period of 40 min, significantly less PrP-GPI accumulated at the cell membrane of m $\beta$ CD pretreated cells (Fig. 3A and Fig. S3, Table S1). Thus, disturbances in the integrity of the cholesterol-rich, ordered membrane domains influence PrP-GPI membrane binding without affecting its diffusion properties (Fig. 3B). This finding agrees with other studies highlighting the necessity of cholesterol for PrP<sup>C</sup> localization at the cell surface (8, 41–43).

Typically, the diffusion of membrane-anchored proteins such as GFP-GPI AP located in the ordered and tightly packed cholesterol-dependent domains is increased upon treatment with m $\beta$ CD (38, 39), and a similar behavior was observed here (Table S2). Confocal FCS data of Cy5-labeled PrP-GPI on SH-SY5Y cell membranes was best fitted with a two-component model (2D, 2p) yielding the diffusion coefficients (D) and fractions of PrP-GPI in solution and bound to the cell

## Early steps in prion protein aggregation on the membrane



**Figure 3. FCS analysis of Cy5-labeled PrP-GPI on the cellular membrane by imaging and dynamic studies.** A, Pearson's correlation coefficients (PCCs) for Cy5-labeled PrP-GPI and GFP-GPI AP on cells subjected to mβCD. Over a time period of 40 min, PrP-GPI accumulation was analyzed for mβCD-treated and nontreated cells. B, average D values for membrane-bound Cy5-labeled PrP-GPI on GFP-GPI AP transfected SH-SY5Y cells for non- and mβCD-treated cells. C, average D values for membrane-bound Cy5-labeled PrP-GPI on LifeAct-GFP transfected SH-SY5Y cells for non- and LatA-treated cells. PrP-GPI was measured before addition of LatA (-LatA) for 30 min and after LatA treatment (+LatA) for 20–75 min. Control measurements were conducted on nontreated LifeAct-GFP cells (nontreated) for the same period of time of PrP incubation (120 min). Mean values ± SD for all ACFs (3, 5, 11) are shown here that are identical to the number of measurements ( $N_m$ ) for confocal FCS. Statistical significance is indicated by \* (with  $p < 0.05$  based on the two-sample t-test) and \*\* indicates no significant difference. D, schematic overview of mβCD and LatA effects on the membrane interaction of Cy5 labeled PrP-GPI.

membrane. The fast component represents PrP-GPI in the extracellular space not linked to the membrane ( $D \sim 30 \mu\text{m}^2/\text{s}$ , fraction 60%), and the slow component corresponds to membrane-bound PrP-GPI ( $D \sim 0.6 \mu\text{m}^2/\text{s}$ , fraction 40%), respectively. Here, we solely focus on the relevant slow component representing membrane-bound PrP-GPI.

The dynamics of Cy5-labeled membrane-bound PrP-GPI remained unaffected by mβCD treatment and retained a diffusion coefficient of  $\sim 0.6 \mu\text{m}^2/\text{s}$  (Fig. 3B, Table S3). This suggests a stronger anchoring of PrP-GPI within the cholesterol-dependent domains of the plasma membrane or the involvement of additional factors, *e.g.*, links to the cytoskeleton. Other studies of GPI-anchored proteins, such as the folate receptor and CD52, indicate a direct or indirect link to the actin cytoskeleton and binding of these GPI-anchored proteins to the plasma membrane (44–46). Such a link could explain the strong anchoring of PrP-GPI to the cellular membrane rendering its mobility unaffected by cholesterol depletion.

To address such an involvement of the cytoskeleton in PrP-GPI interactions on the membrane, we disrupted the cytoskeleton by exposing the cells to LatA (47). This treatment had no significant effect on the fraction of PrP-GPI not bound to the membrane (Fig. S4) and also did not render membrane-

bound PrP-GPI more mobile as could be expected based on previous observations with proteins carrying a transmembrane domain such as the epidermal growth factor receptor (EGFR). Bag *et al.* showed an increase in both the fractions of slow-diffusing and fast-diffusing EGFR populations after LatA treatment that were attributed to synergistic effects of EGFR clustering on removal of the cytoskeleton barrier and a release of cytoskeleton-bound EGFR, respectively (38, 48). In contrast, PrP-GPI cytoskeleton disruption caused a significant decrease in the diffusion coefficients from  $0.6 \pm 0.11$  to  $0.4 \pm 0.12 \mu\text{m}^2/\text{s}$  for membrane-bound PrP-GPI (Fig. 3C; Table S4; Fig. S5 shows confocal images of Cy5-labeled PrP-GPI bound to LifeAct-GFP transfected SH-SY5Y cells). Slower dynamics associated with clustering have been described previously for other peptides and proteins, including PrP itself (49, 50). Control measurements with GFP-GPI AP showed no effect of LatA treatment on mobility of this GPI-anchored membrane probe and exclude a general effect on GPI-anchored proteins (Fig. S6, Table S5).

## Discussion

Elucidating the pathophysiologic events in prion diseases involves understanding the trigger(s) of the conformational change of cellular (PrP<sup>C</sup>) into scrapie prion protein (PrP<sup>Sc</sup>) that further

propagates PrP<sup>C</sup> misfolding and aggregation. To this end, recent studies describe fibril fragmentation and elongation of individual recombinant murine PrP aggregates from seeded aggregation in the test tube (51, 52). But so far, experimental studies have been very limited in directly analyzing the earliest events of PrP misfolding at the cellular membrane of live cells, the initial site of prion infection, by a lack of suitably modified PrP variants and sophisticated experimental setups. Here, application of a semi-synthesis strategy offers a unique opportunity to access homogeneous membrane-anchored Cy5-labeled PrP (PrP-GPI) allowing to directly observe PrP on the cellular membrane. SR images confirmed a native-like membrane localization of Cy5-labeled PrP-GPI on SH-SY5Y cells. Upon manipulating the integrity of the cholesterol-rich, ordered membrane domains in the cell membrane, membrane binding of PrP-GPI decreased but the diffusion dynamics of membrane-bound PrP-GPI remained unaffected. Cytoskeleton disruption, however, caused slower diffusion of PrP-GPI on the membrane. We propose that these slower dynamics of Cy5-labeled PrP-GPI at the membrane are linked to PrP clustering and constitute the initial step of PrP aggregation. Providing direct evidence for PrP clustering on live cells is quite challenging. For example, Goold *et al.* (8) have previously analyzed a PrP knockdown cell line expressing epitope-tagged PrP<sup>C</sup> upon infection with exogenous PrP<sup>Sc</sup> by immunostaining. Shortly after prion exposure, PrP<sup>Sc</sup> was detected on the plasma membrane by immunostaining. This is, however, only feasible on fixed cells and impedes dynamic studies. According to the picket-fence model by Fujiwara *et al.* (34–36), the plasma membrane consists of membrane compartments formed due to partitioning of the entire plasma membrane by the actin cytoskeleton (fence) and transmembrane proteins anchored to the cytoskeleton (pickets, Fig. 3D). The hydrodynamic friction of the immobilized transmembrane proteins causes the diffusion of membrane components around them to slow down. Thus the physical and diffusion barriers provided by the cytoskeleton and the immobilized transmembrane proteins provide an explanation for plasma membrane molecules undergoing short-range free diffusion within a fence with a diffusivity similar to free diffusion in model membranes, as described by the fluid mosaic model (53), but also slower long-range diffusion across multiple fences. By inhibiting actin polymerization, a physical and diffusion barrier provided by the cytoskeleton was removed, which enabled PrP-GPI clustering and aggregation on the cellular membrane as an early step in PrP<sup>C</sup> conversion (Fig. 3D). Our findings suggest that an intact actin cytoskeleton can act as a barrier for the conversion of PrP<sup>C</sup> into PrP<sup>Sc</sup> on cell membranes. They open new avenues for understanding the molecular basis of the early steps of PrP aggregation as well as routes to interfere with these steps to prevent prion protein-based diseases.

## Experimental procedures

### Protein expression and purification

The PrP- $\alpha$ -thioester (aa 23–231) was obtained according to previously established procedures in the Becker group (20, 22, 54). Briefly, a pTWIN1 plasmid containing a construct of PrP

fused to *Mxe* GyrA intein and a chitin-binding domain (CBD) was transformed into *E. coli* chemical-competent Rosetta 2 cells (Fig. S7). After expression in inclusion bodies, the fusion construct was solubilized and purified under denaturing conditions using immobilized metal affinity chromatography (IMAC). MESNA-mediated intein cleavage and concomitant thioester formation proceeded in 4 M urea buffer (pH 8) supplemented with 500 mM sodium 2-mercaptoethanesulfonate (MESNA) (Fig. S8). The crude reaction mixture was purified *via* preparative reversed-phase high-performance liquid chromatography (RP-HPLC). Desired fractions were identified *via* electrospray ionization–mass spectrometry (ESI-MS) operating in positive ion mode, combined and following to lyophilization stored at  $-80^{\circ}\text{C}$ . Purity of the isolated  $\alpha$ -thioester was assessed *via* analytical RP-HPLC (Fig. S9).

### Folding of Cy5-labeled PrP variant

Folding of the Cy5-labeled PrP variant equipped with a GPI anchor mimic into its native structure was accomplished according to a protocol from Chu *et al.* (22). Unless otherwise stated, all steps were performed at  $4^{\circ}\text{C}$ . A solution of denatured modified PrP in 6 M Gdn-HCl, 50 mM Tris-HCl buffer (pH 8) was stepwise diluted to 2.5 M Gdn-HCl, using 20 mM sodium acetate buffer (pH 5), containing a redox system of 0.3 and 3 mM oxidized and reduced glutathione (GSSG, GSH), and additionally 20 mM *N*-octyl- $\beta$ -D-glucopyranoside (OG). After the folding reaction, PrP was dialyzed against 20 mM sodium acetate buffer (pH 5), with 20 mM OG, respectively, using Slide-A-Lyzer cassettes with MWCO of 10 kDa. Precipitates of misfolded protein were separated *via* centrifugation at 14,000g for 15 min. Supernatants containing the folded PrP variant were stored at  $-80^{\circ}\text{C}$ .

### SDS–polyacrylamide gel electrophoresis (SDS-PAGE)

Protein analysis was carried out by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) based on a protocol from Laemmli *et al.* (55) using 15% acrylamide gels under reducing conditions. Samples were treated in 1:1 (v/v) ratio with SDS-loading buffer (pH 6.8), containing 0.5 M Tris-HCl, 6% (w/v) SDS, 35% (w/v) glycerol, 3.5% (v/v)  $\beta$ -mercaptoethanol, 0.05% (w/v) bromophenol blue, boiled at  $95^{\circ}\text{C}$ , and loaded onto the stacking gel. Prior to that any salts in higher concentrations had been removed *via* precipitation with 40% (v/v) trichloroacetic acid (TCA). Applied voltage on power source from VWR was set to 250 V for 35 min. Gels were stained with Coomassie Brilliant Blue R-250 or silver (56). Detection was performed on ChemiDoc MP Imaging System from Bio-Rad with Image Lab 5.1 software.

### Solid-phase peptide synthesis (SPPS)

SPPS was performed applying Fmoc-strategy on a preloaded Fmoc-A-Wang resin, in scales of 0.03–0.25 mmol to afford a peptide based on the sequence H – CKGENLYFQSKAAKK-PPO<sub>3</sub>-A – OH, according to a protocol from Olschewski *et al.* (20). Coupled amino acids carried orthogonal side-chain

## Early steps in prion protein aggregation on the membrane

protecting groups as follows: Lys(Boc), Lys(Mtt) and Lys(ivDde), respectively, Ala, Ser(tBu), Gln(Trt), Phe, Tyr(tBu), Leu, Asn(Trt), Glu(OTBu), Gly, and Boc protected Cys(Trt). Synthesis was accomplished either manually in syringes and glass frits (pore size 2) or automatically using CEM Liberty Blue, Automated Microwave Peptide Synthesizer (CEM). For deprotection of Fmoc, a solution of 20% (v/v) piperidine in *N,N*-dimethylformamide (DMF) was used in cycles of 3 and 7 min. All amino acids were coupled for 30 min in amounts of 2.5eq and 4.8eq, respectively, using either 2.38eq 0.5 M (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) in DMF and 5eq *N,N*-diisopropylethylamine (DIEA) or 4.5eq 0.5 M *N,N*-diisopropylcarbodiimide (DIC) and 5eq 1 M Oxyma in DMF. To enhance solubility, polyethyleneglycol polyamide oligomer (PPO) as trimer was introduced, using first 10eq succinic anhydride in 5eq 0.5 M 1-hydroxybenzotriazole (HOBt) in DMF and 6eq DIEA, second 20eq 0.5 M 1,1'-carbonyldiimidazole (CDI) in DMF, and last 12eq of each, 0.5 M HOBt and 4,7,10-trioxatridecane-1,13-diamine. All steps were conducted for 30 min. For lipidation,  $\epsilon$ -amino groups of lysine 11 and 14 were palmitoylated. After selective removal of orthogonal methyltrityl (Mtt) protective groups with 1% (v/v) trifluoroacetic acid (TFA), 1% (v/v) triisopropylsilane (TIS) in dichloromethane (DCM), palmitoylation was carried out with 20eq palmitoyl chloride, 20eq HOBt, and 22eq triethylamine in DCM:DMF (3:1) solution for 12 h. Coupling of the cyanine 5 (Cy5) dye to  $\epsilon$ -amino group of lysine 2 was performed over 1 h with *in situ* activation using 1.5eq Cy5 with 1.44eq 0.5 M HBTU in DMF and 3eq DIEA. Cy5 synthesis was accomplished in three steps, according to protocols from Yamane *et al.*, Zhang *et al.* and Korbel *et al.* (57–59) (Fig. S10–13, Scheme S1). At the end of SPPS, the peptide was cleaved off from resin through incubation with a solution of 92.5% (v/v) TFA, 5% (v/v) TIS, 2.5% (v/v) dd H<sub>2</sub>O for 2.5 h. The crude peptide was obtained through precipitation with cooled diethyl ether, subsequently dissolving in acetonitrile:dd H<sub>2</sub>O (1:1), 0.1% (v/v) TFA and lyophilization. For purification, semi- and preparative RP-HPLC was conducted. The crude peptide was dissolved in 6 M Gdn-HCl buffer (pH 4.7). Desired fractions were identified *via* ESI-MS operating in positive ion mode, combined and following to lyophilization stored at –20 °C (Table S6). Purity of the Cy5-labeled peptide was assessed *via* analytical RP-HPLC (Fig. S14).

### Expressed protein ligation (EPL)

The ligation between PrP  $\alpha$ -thioester (aa 23–231) and the Cy5-labeled, lipidated peptide proceeded under argon at 37 °C and shaking at 600 rpm. A 2.5-fold excess of the peptide was subjected to 1 mM of PrP  $\alpha$ -thioester. The two components reacted in degassed buffers (pH 7.2) consisting of 6 M Gdn-HCl, 0.2 M Na<sub>2</sub>HPO<sub>4</sub>, with 20 mM TCEP and as thiol catalyst 30 mM 4-mercaptophenylacetic acid (MPAA) for 6 h. Progress was monitored by analytical RP-HPLC (Fig. S15, Table S7). The reaction was complete as judged by time-dependent HPLC traces revealing consistent integrated peak

areas of the ligation product and LC/MS spectra exposing complete hydrolysis of the thioester. Subsequently, the reaction mixture was diluted with acidic 6 M Gdn-HCl buffer (pH 4.7) and subjected to RP-HPLC. Desired fractions were identified *via* ESI-MS operating in positive ion mode, combined and following to lyophilization stored at –80 °C. Purity of Cy5-labeled PrP variant containing a GPI anchor mimic was assessed *via* analytical RP-HPLC (Figs. S16 and S17).

### HPLC and mass spectrometry

RP-HPLC was conducted on a Waters Auto Purification HPLC/MS system (3100 Mass Detector, 2545 Binary Gradient Module, 2767 Sample Manager, 2489 UV/Visible Detector) and a Varian ProStar HPLC system, respectively. On a semi- and preparative scale, separation was achieved using Kromasil (300–10-C4, 250 × 21.2 mm and 250 × 10 mm, 10  $\mu$ m particle size) and Grace Vydac C4 columns (250 × 22 mm and 250 × 10 mm, 5  $\mu$ m particle size) running linear gradients of 30–60% for PrP  $\alpha$ -thioester, 30–90% for peptide, and lipidated PrP variant of buffer B (acetonitrile +0.05% TFA) in buffer A (dd H<sub>2</sub>O + 0.05% TFA) over 60 min. Analytical LC/MS was performed using a Kromasil C4 column (300-5-C4, 50 × 4.6 mm, 5  $\mu$ m particle size) at a flow rate of 1 ml/min running linear gradients of 5–65% or 5–95% over 10 min with buffer compositions and ascribed compounds as mentioned above. Analytical RP-HPLC was conducted on a Dionex Ultimate 3000 instrument using a Kromasil C4 column (300-5-C4, 150 × 4.6 mm, 5  $\mu$ m particle size) at a flow rate of 1 ml/min running linear gradients of 5–65% for the PrP  $\alpha$ -thioester, 5–95% for the peptide, and lipidated PrP variant of buffer B (acetonitrile +0.08% TFA) in buffer A (dd H<sub>2</sub>O + 0.1% TFA) over 30 and 40 min, respectively. As required, HPLC traces were monitored at absorptions of 214 and 280 nm and at emission of 650 nm. The injection peak present in 0–5 min of the HPLC runs was cut off in the depicted chromatograms. HPLC traces of the ligation time courses show only time periods comprising the peaks used for integration. Mass spectra from Waters Auto Purification HPLC/MS system were acquired by electrospray ionisation (ESI) operating in positive ion mode. Deconvolution was accomplished using the softwares MassLynx and MagTran. All raw data were exported and processed using OriginPro.

### Circular dichroism (CD)

CD spectra were recorded on a Chirascan Plus CD-spectrophotometer from Applied Photophysics using a micro cuvette with 1 mm path length from Hellma Analytics. Each spectrum was acquired at 25 °C from 190 to 260 nm in 1 nm steps. In total, ten measurements were averaged, and the background was subtracted. The raw data was exported from Pro-Data software and further processed using OriginPro. Spectra were analyzed regarding their secondary structure by the curve-fitting software CDNN from Böhm *et al.* (60). For each measurement, a final protein concentration of 4–10  $\mu$ M was used that previously had been determined by NanoDrop 2000c from Fisher-Scientific. For folded recombinant, lipidated

and labeled PrP variants, respectively, calculated molar extinction coefficients at 280 nm obtained from Expasy-ProtParam (<https://web.expasy.org/protparam>) were used in combination with MW values as follows: recombinant PrP (aa 23–231) 63,495 M<sup>-1</sup> cm<sup>-1</sup>, 23,200.6; lipidated PrP 64,985 M<sup>-1</sup> cm<sup>-1</sup>, 26,352.6 Da, and Cy5-labeled PrP 26,803.9 Da.

### Cell culture, staining, and treatment

SH-SY5Y and stably transfected LifeAct-GFP SH-SY5Y cells were cultivated in DMEM medium supplemented with 10% FBS and 1% PS at 37 °C in 5% (v/v) CO<sub>2</sub> humidified environment. For the staining of the cell membrane using CellMask green, cells were incubated with dilutions in live cell imaging solution of 1:1000 for 30 min at 37 °C in 5% (v/v) CO<sub>2</sub> humidified environment. Transfection of GFP-GPI AP by electroporation into live SH-SY5Y cells was accomplished on a Neon Transfection System from Life Technologies. Approximately 90% confluent cells grown in a 25 cm<sup>2</sup> culture flask were washed with 1× PBS and collected after trypsinization with 1× Trypsin solution *via* centrifugation for 3 min at 3000 rpm using a 5810 centrifuge from Eppendorf. Pelleted cells were resuspended in 12.5 µl of R-buffer, mixed with ~1 µg of plasmid per 8× well chamber, drawn into a 10 µl Neon transfection tip, and electroporated at 1200 V for 20 ms with three pulses in a Neon transfection tube containing 3 ml of E-buffer. After transfection, cells were plated and grown in culture medium at 37 °C in 5% (v/v) CO<sub>2</sub> humidified environment for 48 h. SH-SY5Y cells were washed twice with 1× Hanks' Balanced Salt Solution (HBSS) before mounting them into the microscope chamber containing 1× HBSS as imaging medium. For drug treatments to inhibit actin polymerization and deplete cholesterol, respectively, the imaging medium was replaced with 3 µM LatA diluted from a 100 µM stock solution in DMSO and 3 mM mβCD, both dissolved in HBSS. Folded PrP variant in sodium acetate buffer containing OG (pH 5) was added to the cells 10× diluted in HBSS to a final concentration of 200 nM. For encapsulation of PrP by Pro-Ject, PrP was treated according to the manufacturer's protocol. For nonlive measurements, cells were post fixed with formaldehyde (3.7% in PBS, 20 min) and mounted adding Roti-Mount FluorCare.

### Structured illumination microscopy (SIM) imaging and colocalization analysis

SR imaging using structured illumination microscopy (SIM) technique was conducted on a Zeiss 710 confocal laser scanning microscope (CLSM) with an Elyra PS.1 system at 37 °C. The 488 nm (for CellMask green excitation) or the 642 nm (for Cy5 excitation) HR-diode laser beam was focused on the sample by an oil immersion objective (Plan-Apochromat DIC M27, 63×, NA1.4). Fluorescence signal from the sample was spectrally filtered *via* an emission filter, namely BP495-575/LP750 for CellMask green or LP655 for Cy5 emission and recorded by an electron multiplying charge-coupled device (EMCCD) camera Andor iXon 897.

Images with a field of view of 1280 × 1280 pixels and pixel sizes of 64 × 64 × 110 nm were acquired in five phases and rotations, using grating periods of 28 and 34 µm for CellMask green and Cy5, respectively. Postmeasurement image reconstruction was accomplished using Zen 2012 SP3 (black) software from Zeiss with the theoretical point spread function (PSF) set to a value of 2, a baseline cut, the SR frequency weighting set to 1, the noise filter (NF) to 4 (for Cy5) and 3 (for CellMask green), and sectioning at 83/83/100. Eventually structured illumination images with a field of view of 2430 × 2430 pixels and pixel sizes of 32 × 32 × 110 nm were obtained. Lateral resolution determined by Zen is 118 nm for CellMask and 129 nm for Cy5 and determination with ImageJ gives values of 122 nm for CellMask and 124 nm for Cy5. For final image representation, SIM images were displayed using 3D shadow rendering and adjusted with regard to their brightness and contrast. For quantitative colocalization analysis, regions of interest (ROIs) with 753 × 313 pixels were cut out.

Thereby, precise local information of PrP within cells could be extracted from the image stacks using ImageJ (61, 62) software with Just Another Colocalization Plugin (JACoP) (30, 63). Several global statistic approaches performing intensity correlation coefficient-based (ICCB) analyses that offer complementary information were applied and compared. Pearson's correlation coefficient (PCC) describes the spread of the pixel distribution within a scatter plot in respect to the fitted line displaying the relationship between the intensities of the two images. Its value lies in the range from 1 to -1, with 1 for complete colocalization and -1 for exclusion (Equation 1).

*Equation 1. Pearson's correlation coefficient (PCC) with A<sub>i</sub> and B<sub>i</sub> as the intensities of channel A and B, a and b as the corresponding mean intensities.*

$$r_p = \frac{\sum_i (A_i - a) \cdot (B_i - b)}{\sqrt{\sum_i (A_i - a)^2 \cdot \sum_i (B_i - b)^2}} \quad (1)$$

To provide statistical significance to the calculated PCCs, Van Steensel's (31) and Costes' (29) approaches were conducted. For the Van Steensel's cross-correlation function (CCF), the PCC is calculated while a shift of one of the images relative to the other is operated. If the resulting plot of the PCC as a function of the displacement shows a bell-shaped curve or a dip, colocalization or exclusion is identified. Depending on the position of the maximum being at 0 or shifted, partial colocalization can be determined. The height correlates with noise and/or differing fluorescence intensities. Costes' approach offers two possibilities, namely automatic thresholding together with a calculation of the respective PCC and by comparing a randomized with the original image an evaluation of the significance (*p*-value) of the PCC, meaning the probability of obtaining the specified PCC by chance. In Costes' automatic thresholding, initial limits are set to the maximum intensity of each channel and progressively decremented. PCCs are calculated for each increment of thresholded image pairs. The final Costes' thresholds are then set to values below which PCC is zero or negative. Another ICCB

## Early steps in prion protein aggregation on the membrane

analysis is provided by Manders' coefficients (27, 28). These values are built by the ratio of the sum of intensities of colocalizing pixels from one channel and its integrated density. Pixels from image A are considered colocalized, if their intensity in channel B is above 0 ( $M_1$ ), and vice versa ( $M_2$ ). Values range from 0 to 1 for non- and complete overlapping events (Equation 2).

Equation 2. Manders' coefficients with  $A_{i,coloc} = A_i$ , if  $B_i > 0$  and  $B_{i,coloc} = B_i$ , if  $A_i > 0$ .

$$M_1 = \frac{\sum_i A_{i,coloc}}{\sum_i A_i} \quad (2)$$
$$M_2 = \frac{\sum_i B_{i,coloc}}{\sum_i B_i}$$

An interpretable representation of colocalization was described by Li *et al.* (64) (see Figs. S18 and S19). A set of two graphs presents the intensity correlation analysis (ICA) results. Normalized intensities (0–1) are plotted as a function of the product  $(A_i - a)(B_i - b)$  for each channel, with the upper-case characters as the current pixel's intensity and the lower-case characters as the channel's mean intensity. For colocalizing pixels, the covariance of both channels is positive, resulting in a dot cloud concentrated on the right side of  $x = 0$ . Non-colocalizing pixels are located on the left side. In case of ambiguous results, the intensity correlation quotient (ICQ) can be determined. It is defined as the ratio of positive  $(A_i - a)(B_i - b)$  products divided by the overall products subtracted by 0.5. Thus, resulting ICQs vary from colocalization with 0.5 to exclusion with  $-0.5$ , whereas random staining and images corrupted by noise give values close to 0.

### Confocal imaging and fluorescence correlation spectroscopy (FCS)

Both confocal imaging and FCS were conducted on an Olympus FV1200 laser scanning confocal microscope from Olympus IX83 equipped with a Microtime 200 upgrade kit for single molecule detection from PicoQuant at 37 °C. The 488 nm argon-ion (for Atto488 and EGFP excitation) or the 635 nm (for Atto655 and Cy5 excitation) laser beam from Melles Griot was focused on the sample by a water immersion objective (UPLSAPO, 60×, NA1.2) from Olympus after being reflected by a dichroic mirror (DM405/488/543/635 bandpass) from Olympus and a scanning mirror unit. The laser powers measured before the objective were 17 and 12  $\mu$ W for the 488 nm and the 635 nm lasers, which correspond to excitation intensities of 17 and 8 kW/cm<sup>2</sup>, respectively (65).

For confocal imaging, the system was operated in scan mode. Fluorescence signal from the sample was passed through the same objective, through a 120  $\mu$ m pinhole in the image plane to block off out-of-focus light, spectrally filtered via a bandpass emission filter, namely BA505-525 for EGFP or BA655 to 755 for Cy5 excitation, from Olympus, and recorded by a photomultiplier detector. Images with a field of view of 512 × 512 pixels and a pixel size of 138 nm were acquired at a scan rate of 12.5  $\mu$ s/pixel.

For confocal FCS measurements, the system was descanned and operated in point mode. Fluorescence signal from the sample was passed through the 120  $\mu$ m pinhole, spectrally filtered by an emission filter, namely 513/17 (for Atto488 or EGFP emission) or 680/42 (for Atto655 or Cy5 emission) from Semrock, and eventually recorded by a sensitive single-photon avalanche photodiode (SPAD) SPCEM-AQR-14 from PerkinElmer, Optoelectronics. Signal detected by the avalanche photodiode was then processed online by the SymPhoTime 64 software correlator from PicoQuant, giving the autocorrelation function (ACF). Postmeasurement fitting was performed in the SymPhoTime 64 software or in Igor Pro 7 from WaveMetrics using the open-source FCS 2.1 script provided by the Wohland laboratory at NUS (available at: [http://www.dbs.nus.edu.sg/lab/BFL/confocal\\_FCS.html](http://www.dbs.nus.edu.sg/lab/BFL/confocal_FCS.html)). The total measurement time for the calibration dyes and on the cells was in the range of 30–40 s.

Prior to conducting FCS measurements on the samples, the system was aligned for performance of the highest SNR achievable by adjusting the pinhole position in  $x$ -,  $y$ -, and  $z$ -directions. To obtain the maximum fluorescence intensity emitted by the respective calibration dyes, an FCS measurement was conducted to generate an ACF, which was then fitted to obtain the structure factor  $K$  (Equation 4) and the molecular brightness ( $\eta$ ) in photon counts per particle per second (cps). The pinhole position was adjusted and FCS measurements repeated until a  $K$  value of 4–6 and the maximum  $\eta$  were achieved. As the water immersion objective used had a cover slip correction collar, this was also adjusted to optimize the brightness. Using the diffusion time of the calibration dye ( $\tau_{D,calibrationdye}$ ) with known diffusion coefficient and  $K$  values extracted from the FCS fits, the effective observation volume was then calculated applying Equations 3–5.

Equation 3. Effective observation volume ( $V_{eff}$ ) in confocal FCS for noninteracting particles, with  $\vec{r}$  as the spatial coordinate and  $MDE(\vec{r})$  the molecular detection efficiency.

$$V_{eff} = \frac{(\iiint_{-\infty}^{\infty} MDE(\vec{r}) dV)^2}{\iiint_{-\infty}^{\infty} (MDE(\vec{r}))^2 dV} = \pi^3 \omega_0^2 z_0 \quad (3)$$

Equation 4. Structure factor  $K$  is defined as the ratio of the axial ( $z_0$ ) and radial ( $\omega_0$ ) distances of the laser focal spot at  $1/e^2$  value of the maximum intensity at the focus of the observation volume.

$$K = \frac{z_0}{\omega_0} \quad (4)$$

Equation 5. Diffusion time and coefficient.

$$\tau_D = \frac{\omega_0^2}{4D} \quad (5)$$

The appropriate ACF fitting models are chosen considering the weight of the noise from each data point, *i.e.*, the standard deviation as described by Koppel (66) and Wohland *et al.* (67). Theoretical models of the ACF  $G(\tau)$  can be described



considering the average number of particles within the observation volume ( $N$ ), the lag time ( $\tau$ ), the diffusion time ( $\tau_D$ ), the structure factor  $K$ , and the convergence value of the ACF at long lag times ( $G_\infty$ ) with an expected value of . In the case of multiple diffusion components,  $G(\tau)$  is expressed as the linear sums of the individual components weighted with their respective mole fractions ( $F_i$ ) of the  $i^{th}$  species. For triplet-state photodynamics,  $F_{trip}$  refers to the fraction and  $\tau_{trip}$  to the relaxation time of the triplet state (68, 69). For the calibration dye solutions, 3D diffusion fitting models with a single component (1p), 3D,1p, or with an additional single triplet contribution (1t), 3D,1p1t, were used (Equation 6). For the membrane measurements, the fitting models used were 2D diffusion with two diffusion components (2p), 2D,2p, or with an additional single triplet contribution, 2D,2p1t (Equation 7). As the photophysical processes of Cy5 are strongly environment sensitive, but not believed to change the diffusion properties drastically, they were neglected during the fitting of the ACF curves and a 2D, 2p model was applied on data from later lag times (70).

Equation 6. Mathematical models for 3D diffusion of a single component (1p) without (upper formula) and with a single triplet contribution (lower formula) for confocal FCS.

$$G_{3D,1p}(\tau) = \frac{1}{N} \left( 1 + \frac{\tau}{\tau_D} \right)^{-1} \left( 1 + \frac{\tau}{K^2 \tau_D} \right)^{-1/2} + G_\infty$$

$$G_{3D,1p1t}(\tau) = \frac{1}{N} \left( 1 + \frac{\tau}{\tau_D} \right)^{-1} \left( 1 + \frac{\tau}{K^2 \tau_D} \right)^{-1/2} \left( 1 + \left( \frac{F_{trip}}{1-F_{trip}} \right) e^{-\frac{\tau}{\tau_{trip}}} \right) + G_\infty \quad (6)$$

Equation 7. Mathematical models for 2D diffusion with two components (2p) without (upper formula) and with a single triplet contribution (lower formula) for confocal FCS.

$$G_{2D,2p}(\tau) = \frac{1}{N} \left( (1-F_2) \left( 1 + \frac{\tau}{\tau_{D1}} \right)^{-1} + F_2 \left( 1 + \frac{\tau}{\tau_{D2}} \right)^{-1} \right) + G_\infty$$

$$G_{2D,2p1t}(\tau) = \frac{1}{N} \left( (1-F_2) \left( 1 + \frac{\tau}{\tau_{D1}} \right)^{-1} + F_2 \left( 1 + \frac{\tau}{\tau_{D2}} \right)^{-1} \right) \left( 1 + \left( \frac{F_{trip}}{1-F_{trip}} \right) e^{-\frac{\tau}{\tau_{trip}}} \right) + G_\infty \quad (7)$$

The fit parameters are the average number of particles  $N$ , diffusion time  $\tau_D$ , triplet relaxation time  $\tau_{trip}$  and  $G_\infty$ . The  $K$  values obtained from the calibration dye solutions were fixed for all sample measurements (Table 1). The apparent  $D$  of the sample ( $D_{sample}$ ) was determined using the known  $D$  of the calibration dye ( $D_{calibrationdye}$ ), namely 400 (71) and 426  $\mu\text{m}^2/\text{s}$  (72, 73) for Atto488 and Atto655, respectively, together with the measured diffusion times of the sample and the calibration dye deriving from the fits of the ACF curve (Equation 8).

Table 1

Typical values of parameters fitted with 3D,1p and 3D,1p1t models for FCS calibration using 2 nM Atto488 and 3.8 nM Atto655 dye in PBS (pH 7.4)

| Fit parameters     | Fitted values      |                     |
|--------------------|--------------------|---------------------|
|                    | Atto488            | Atto655             |
| $N$                | 0.48 ± 0.000       | 0.85 ± 0.021        |
| $\tau_D$ (μs)      | 22.6 ± 0.51        | 26.5 ± 0.13         |
| $\tau_{trip}$ (μs) | 3.5 ± 0.72         | -                   |
| $F_{trip}$         | 0.2 ± 0.02         | -                   |
| $K$                | 4.2 ± 0.12         | 4.5 ± 0.54          |
| $G_\infty$         | 0.00036 ± 0.000243 | -0.00009 ± 0.000748 |

The fitted values are given as value ± error of fit.

Equation 8. Relationship between diffusion times and coefficients of the sample and calibration dye.

$$D_{sample} = \frac{\tau_{D, calibration dye} \cdot D_{calibration dye}}{\tau_{D, sample}} \quad (8)$$

In our studies, FCS measurements were conducted at  $z$ -positions below the upper membrane at the cell boundary. Cells were incubated with PrP and Project for 30 min, washed with HBSS buffer, and then subjected to treatments with methyl-β-cyclodextrin (mβCD) or latrunculin A (LatA) in concentrations of 3 mM and 3 μM, respectively. It should be noted that measurements at the upper membrane were occasionally hampered by PrP in solution that freely diffused and showed a stronger tendency to aggregate, resulting in a large number of spikes present in the fluorescence intensity traces complicating ACF analysis. This was rectified by segmenting the intensity trace in the absence of large fluorescence spikes and computing the ACFs thereafter.

#### Imaging total internal reflection-FCS (ITIR-FCS)

Quantitative images of FCS parameters were obtained applying ITIR-FCS on an IX2-RFAEVA-2 total internal reflection fluorescence module on an IX71 microscope (Olympus) equipped with a high NA oil-immersion objective (PlanApo, 100×, 1.45, Olympus) and a back-illuminated EMCCD camera (Andor iXon 860, 128 × 128 pixels) at 37 °C in 5% (v/v) CO<sub>2</sub> humidified environment. The system was optimized as described previously (74, 75). The air-cooled 488 nm argon-ion (for EGFP excitation) laser beam from Spectra-Physics Lasers was focused on the sample after being reflected by a combination of tilting mirrors and a dichroic mirror (495LP). TIR was achieved by adjusting the same combination of tilting mirrors to control the incident angle of the laser beam. A stack of 50,000 images was collected by the CCD chip with 2 ms time resolution. Andor Solis was used as the acquisition software and operated in kinetic mode. The fluorescence intensity fluctuations at each pixel of a ROI with a typical size of 5.04 × 5.04 μm<sup>2</sup> containing 21 × 21 pixels on the sample were then bleach-corrected with a fourth-order polynomial, processed to yield ACFs and fitted according to Equation 9 for a one particle diffusion model by ImageJ (61, 62) software using the ImFCS 1.52 (76) plugin to produce

## Early steps in prion protein aggregation on the membrane

quantitative maps of the diffusion coefficients ( $D$ ) and the number of particles ( $N$ ).

**Equation 9.** ITIR-FCS fitting model for 2D diffusion with one component (1p).

$$G(\tau) = \frac{1}{N} \left[ \operatorname{erf} \left( p(\tau) + \frac{1}{p(\tau)\sqrt{\pi}} \left( e^{-(p(\tau))^2} - 1 \right) \right) \right]^2 + G_{\infty}; \quad p(\tau) = \frac{a}{2\sqrt{D\tau + \sigma^2}} \quad (9)$$

In the above equation,  $G(\tau)$  is the ACF as a function of the correlation time ( $\tau$ ) and  $N$ ,  $a$ ,  $D$ , and  $\sigma$  are the number of particles per pixel, pixel side length, diffusion coefficient, and standard deviation of the Gaussian approximation of the microscope PSF, respectively. The pixel size  $a$  of the CCD chip in the camera is 24  $\mu\text{m}$ , which corresponds to 240 nm in the sample plane.  $G_{\infty}$  is the convergence value of the ACF at very long correlation time.  $N$ ,  $D$ , and  $G_{\infty}$  were used as fit parameters.

### Data availability

We have included all data on protein synthesis and characterization in this article and the accompanying [supporting information](#). Microscopy data analyzed for the article is summarized in figures and tables in here and in the [supporting information](#). Additional images and FCS data sets are available upon request from Christian Becker, Institute of Biological Chemistry, University of Vienna, Austria ([christian.becker@univie.ac.at](mailto:christian.becker@univie.ac.at)), or Thorsten Wohland, Departments of Biological Sciences and Chemistry and Centre for Bioimaging Sciences (CBIS), National University of Singapore (NUS), Singapore ([twohland@nus.edu.sg](mailto:twohland@nus.edu.sg)).

**Supporting information**—This article contains [supporting information](#) (27–29, 31, 57–59, 64, 78–80).

**Acknowledgments**—The authors would like to thank H. Geisler, F. Weber, L. Göschl, and M. Klingler for support with sample preparation. C. Araman, K. Thewes, and E. Attakpah are kindly acknowledged for guidance on peptide synthesis and microscopy. The authors also thank N. V. S. Ashwin for the open-source FCS 2.1 script for Igor Pro 7 software ([http://www.dbs.nus.edu.sg/lab/BFL/confocal\\_FCS.html](http://www.dbs.nus.edu.sg/lab/BFL/confocal_FCS.html)).

**Author contributions**—S. H.: Conceptualization, Data curation, Formal analysis, Investigation, Writing - original draft, Writing - review and editing; X. W. N.: Data curation, Formal analysis, Investigation, Writing - review and editing; D. L.: Formal analysis, Investigation; T. W.: Conceptualization, Resources, Formal analysis, Supervision, Writing - review and editing; C. F. W. B.: Conceptualization, Resources, Data curation, Supervision, Writing - original draft, Project administration, Writing - review and editing.

**Funding and additional information**—S. H. is grateful for financial support by Wien Kultur. T. W. received support from the Singapore Ministry of Education (R-154-000-B53-114). C. F. W. B. was funded by the Vienna Science and Technology Fund (WWTF, LS17-008).

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: ACF, autocorrelation function; CBD, chitin-binding domain; CCF, cross-correlation function; CD, circular dichroism; CDI, carbonyldiimidazole; DCM, dichloromethane; EGFR, epidermal growth factor receptor; EPL, expressed protein ligation; EMCCD, electron multiplying charge-coupled device; ESI-MS, electrospray ionization–mass spectrometry; FCS, fluorescence correlation spectroscopy; GPI, glycosylphosphatidylinositol; HBSS, Hanks' Balanced Salt Solution; ICA, intensity correlation analysis; ICQ, intensity correlation quotient; ITIR-FCS, imaging total internal reflection–FCS; m $\beta$ CD, methyl- $\beta$ -cyclodextrin; PCC, Pearson's correlation coefficient; PrP<sup>Sc</sup>, scrapie prion protein; PrP<sup>C</sup>, cellular prion protein; PSF, point spread function; ROI, region of interest; RP-HPLC, reversed-phase high-performance liquid chromatography; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; SPPS, solid-phase peptide synthesis; SR-SIM, superresolution structured illumination microscopy; TCA, trichloroacetic acid; TIS, triisopropylsilane; TSE, transmissible spongiform encephalopathy.

### References

- Weissmann, C. (1999) Molecular genetics of transmissible spongiform encephalopathies. *J. Biol. Chem.* **274**, 3–6
- Prusiner, S. B. (1982) Novel proteinaceous infectious particles cause scrapie. *Science* **216**, 136–144
- Prusiner, S. B. (1998) Prions. *Proc. Natl. Acad. Sci. U. S. A.* **95**, 13363–13383
- Aguzzi, A., and Weissmann, C. (1998) Prion diseases. *Haemophilia* **4**, 619–627
- Stahl, N., Borchelt, D. R., Hsiao, K., and Prusiner, S. B. (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. *Cell* **51**, 229–240
- Wang, F., Yang, F., Hu, Y., Wang, X., Jin, C., and Ma, J. (2007) Lipid interaction converts prion protein to a PrP<sup>Sc</sup>-like proteinase K-resistant conformation under physiological conditions. *Biochemistry* **46**, 7045–7053
- Wang, F., Wang, X., Yuan, C. G., and Ma, J. (2010) Generating a prion with bacterially expressed recombinant prion protein. *Science* **327**, 1132–1135
- Goold, R., Rabbani, S., Sutton, L., Andre, R., Arora, P., Moonga, J., Clarke, A. R., Schiavo, G., Jat, P., Collinge, J., and Tabrizi, S. J. (2011) Rapid cell-surface prion protein conversion revealed using a novel cell system. *Nat. Commun.* **2**, 281
- Borchelt, D. R., Taraboulos, A., and Prusiner, S. B. (1992) Evidence for synthesis of scrapie prion proteins in the endocytic pathway. *J. Biol. Chem.* **267**, 16188–16199
- Gilch, S., Winklhofer, K. F., Groschup, M. H., Nunziante, M., Lucassen, R., Spielhauer, C., Muranyi, W., Riesner, D., Tatzelt, J., and Schätzl, H. M. (2001) Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. *EMBO J.* **20**, 3957–3966
- Baron, G. S., Wehrly, K., Dorward, D. W., Chesebro, B., and Caughey, B. (2002) Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP(Sc)) into contiguous membranes. *EMBO J.* **21**, 1031–1040
- Baron, G. S., and Caughey, B. (2003) Effect of glycosylphosphatidylinositol anchor-dependent and -independent prion protein association with model raft membranes on conversion to the protease-resistant isoform. *J. Biol. Chem.* **278**, 14883–14892
- Chesebro, B., Trifilo, M., Race, R., Meade-White, K., Teng, C., LaCasse, R., Raymond, L., Favara, C., Baron, G., Priola, S., Caughey, B., Masliah, E., and Oldstone, M. (2005) Anchorless prion protein results in infectious amyloid disease without clinical scrapie. *Science* **308**, 1435–1439

14. Gorodinsky, A., and Harris, D. A. (1995) Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. *J. Cel. Biol.* **129**, 619–627
15. Aguzzi, A., and Heppner, F. L. (2000) Pathogenesis of prion diseases: A progress report. *Cell Death Differ.* **7**, 889–902
16. Weissmann, C. (1994) Molecular biology of prion diseases. *Trends Cell Biol.* **4**, 10–14
17. Muir, T. W., Sondhi, D., and Cole, P. A. (1998) Expressed protein ligation: A general method for protein engineering. *Proc. Natl. Acad. Sci. U. S. A.* **95**, 6705–6710
18. Thompson, R. E., and Muir, T. W. (2019) Chemoenzymatic semisynthesis of proteins. *Chem. Rev.*
19. Conibear, A. C., Watson, E. E., Payne, R. J., and Becker, C. F. W. (2018) Native chemical ligation in protein synthesis and semi-synthesis. *Chem. Soc. Rev.* **47**, 9046–9068
20. Olschewski, D., Seidel, R., Miesbauer, M., Rambold, A. S., Oesterhelt, D., Winkhofer, K. F., Tatzelt, J., Engelhard, M., and Becker, C. F. (2007) Semisynthetic murine prion protein equipped with a GPI anchor mimic incorporates into cellular membranes. *Chem. Biol.* **14**, 994–1006
21. Becker, C. F., Liu, X., Olschewski, D., Castelli, R., Seidel, R., and Seeburger, P. H. (2008) Semisynthesis of a glycosylphosphatidylinositol-anchored prion protein. *Angew. Chem. Int. Ed. Engl.* **47**, 8215–8219
22. Chu, N. K., Shabbir, W., Bove-Fenderson, E., Araman, C., Lemmens-Gruber, R., Harris, D. A., and Becker, C. F. (2014) A C-terminal membrane anchor affects the interactions of prion proteins with lipid membranes. *J. Biol. Chem.* **289**, 30144–30160
23. Araman, C., Thompson, R. E., Wang, S., Hackl, S., Payne, R. J., and Becker, C. F. W. (2017) Semisynthetic prion protein (PrP) variants carrying glycan mimics at position 181 and 197 do not form fibrils. *Chem. Sci.* **8**, 6626–6632
24. Pan, K. M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R. J., Cohen, F. E., and Prusiner, S. B. (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. *Proc. Natl. Acad. Sci. U. S. A.* **90**, 10962–10966
25. Han, S., and Hill, A. F. (2008) Analysis of PrP conformation using circular dichroism. *Methods Mol. Biol.* **459**, 145–159
26. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., and Danielsen, M. (1987) Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. *Proc. Natl. Acad. Sci. U. S. A.* **84**, 7413–7417
27. Manders, E. M., Verbeek, F. J., and Aten, J. A. (1993) Measurement of colocalization of objects in dual-colour confocal images. *J. Microsc.* **169**, 375–382
28. Manders, E. M., Stap, J., Brakenhoff, G. J., van Driel, R., and Aten, J. A. (1992) Dynamics of three-dimensional replication patterns during the S-phase, analysed by double labelling of DNA and confocal microscopy. *J. Cell Sci.* **103**(Pt 3), 857–862
29. Costes, S. V., Daelemans, D., Cho, E. H., Dobbin, Z., Pavlakis, G., and Lockett, S. (2004) Automatic and quantitative measurement of protein-protein colocalization in live cells. *Biophys. J.* **86**, 3993–4003
30. Bolte, S., and Cordelières, F. P. (2006) A guided tour into subcellular colocalization analysis in light microscopy. *J. Microsc.* **224**, 213–232
31. van Steensel, B., van Binnendijk, E. P., Hornsby, C. D., van der Voort, H. T., Krozowski, Z. S., de Kloet, E. R., and van Driel, R. (1996) Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. *J. Cell Sci.* **109**(Pt 4), 787–792
32. Rigler, R., and Mets, Ü. (1992) Diffusion of single molecules through a Gaussian laser beam. *SPIE Laser Spectrosc. Biomol.* **1921**, 239–248
33. Simons, K., and Ikonen, E. (1997) Functional rafts in cell membranes. *Nature* **387**, 569–572
34. Ritchie, K., Iino, R., Fujiwara, T., Murase, K., and Kusumi, A. (2003) The fence and picket structure of the plasma membrane of live cells as revealed by single molecule techniques (Review). *Mol. Membr. Biol.* **20**, 13–18
35. Fujiwara, T., Ritchie, K., Murakoshi, H., Jacobson, K., and Kusumi, A. (2002) Phospholipids undergo hop diffusion in compartmentalized cell membrane. *J. Cell Biol.* **157**, 1071–1081
36. Kusumi, A., Suzuki, K. G., Kasai, R. S., Ritchie, K., and Fujiwara, T. K. (2011) Hierarchical mesoscale domain organization of the plasma membrane. *Trends Biochem. Sci.* **36**, 604–615
37. Bernardino de la Serna, J., Schutz, G. J., Eggeling, C., and Cebebauer, M. (2016) There is no simple model of the plasma membrane organization. *Front. Cell Dev. Biol.* **4**, 106
38. Huang, S., Lim, S. Y., Gupta, A., Bag, N., and Wohland, T. (2017) Plasma membrane organization and dynamics is probe and cell line dependent. *Biochim. Biophys. Acta* **1859**, 1483–1492
39. Ng, X. W., Teh, C., Korzh, V., and Wohland, T. (2016) The secreted signaling protein Wnt3 is associated with membrane domains in vivo: A SPIM-FCS study. *Biophys. J.* **111**, 418–429
40. Zidovetzki, R., and Levitan, I. (2007) Use of cyclodextrins to manipulate plasma membrane cholesterol content: Evidence, misconceptions and control strategies. *Biochim. Biophys. Acta* **1768**, 1311–1324
41. Gilch, S., Kehler, C., and Schatzl, H. M. (2006) The prion protein requires cholesterol for cell surface localization. *Mol. Cell Neurosci.* **31**, 346–353
42. Sanghera, N., and Pinheiro, T. J. (2002) Binding of prion protein to lipid membranes and implications for prion conversion. *J. Mol. Biol.* **315**, 1241–1256
43. Taylor, D. R., and Hooper, N. M. (2006) The prion protein and lipid rafts (Review). *Mol. Membr. Biol.* **23**, 89–99
44. Raghupathy, R., Anilkumar, A. A., Polley, A., Singh, P. P., Yadav, M., Johnson, C., Suryawanshi, S., Saikam, V., Sawant, S. D., Panda, A., Guo, Z., Vishwakarma, R. A., Rao, M., and Mayor, S. (2015) Transbilayer lipid interactions mediate nanoclustering of lipid-anchored proteins. *Cell* **161**, 581–594
45. Saha, S., Lee, I. H., Polley, A., Groves, J. T., Rao, M., and Mayor, S. (2015) Diffusion of GPI-anchored proteins is influenced by the activity of dynamic cortical actin. *Mol. Biol. Cell* **26**, 4033–4045
46. Rao, M., and Mayor, S. (2014) Active organization of membrane constituents in living cells. *Curr. Opin. Cell Biol.* **29**, 126–132
47. Bacia, K., Scherfeld, D., Kahya, N., and Schwille, P. (2004) Fluorescence correlation spectroscopy relates rafts in model and native membranes. *Biophys. J.* **87**, 1034–1043
48. Bag, N., Huang, S., and Wohland, T. (2015) Plasma membrane organization of epidermal growth factor receptor in resting and ligand-bound states. *Biophys. J.* **109**, 1925–1936
49. Bag, N., Ali, A., Chauhan, V. S., Wohland, T., and Mishra, A. (2013) Membrane destabilization by monomeric hIAPP observed by imaging fluorescence correlation spectroscopy. *Chem. Commun. (Camb.)* **49**, 9155–9157
50. Yu, H., Dee, D. R., Liu, X., Brigley, A. M., Sosova, I., and Woodside, M. T. (2015) Protein misfolding occurs by slow diffusion across multiple barriers in a rough energy landscape. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 8308–8313
51. Sang, J. C., Meisl, G., Thackray, A. M., Hong, L., Ponjavic, A., Knowles, T. P. J., Bujdoso, R., and Klenerman, D. (2018) Direct observation of murine prion protein replication *in Vitro*. *J. Am. Chem. Soc.* **140**, 14789–14798
52. Sang, J. C., Lee, J. E., Dear, A. J., De, S., Meisl, G., Thackray, A. M., Bujdoso, R., Knowles, T. P. J., and Klenerman, D. (2019) Direct observation of prion protein oligomer formation reveals an aggregation mechanism with multiple conformationally distinct species. *Chem. Sci.* **10**, 4588–4597
53. Singer, S. J., and Nicolson, G. L. (1972) The fluid mosaic model of the structure of cell membranes. *Science* **175**, 720–731
54. Chu, N. K., and Becker, C. F. (2009) Semisynthesis of membrane-attached prion proteins. *Methods Enzymol.* **462**, 177–193
55. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680
56. Sasse, J., and Gallagher, S. R. (2004) Staining proteins in gels. *Curr. Protoc. Immunol.* Chapter 8:Unit 8.9
57. Yamane, T., Hanaoka, K., Muramatsu, Y., Tamura, K., Adachi, Y., Miyashita, Y., Hirata, Y., and Nagano, T. (2011) Method for enhancing cell penetration of Gd<sup>3+</sup>-based MRI contrast agents by conjugation with hydrophobic fluorescent dyes. *Bioconjug. Chem.* **22**, 2227–2236
58. Zhang, L., Er, J. C., Li, X., Heng, J. J., Samanta, A., Chang, Y.-T., and Lee, C.-L. K. (2015) Development of fluorescent probes specific for parallel-stranded G-quadruplexes by a library approach. *Chem. Commun.* **51**, 7386–7389

## Early steps in prion protein aggregation on the membrane

59. Korbel, G. A., Lalic, G., and Shair, M. D. (2001) Reaction microarrays: A method for rapidly determining the enantiomeric excess of thousands of samples. *J. Am. Chem. Soc.* **123**, 361–362
60. Böhm, G., Muhr, R., and Jaenicke, R. (1992) Quantitative analysis of protein far UV circular dichroism spectra by neural networks. *Protein Eng. Des. Selection* **5**, 191–195
61. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J.-Y., White, D. J., Hartenstein, V., Eliceiri, K., Tomancak, P., et al. (2012) Fiji: An open-source platform for biological-image analysis. *Nat. Methods* **9**, 676
62. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671–675
63. Cordelières, F., and Bolte, S. (2008) *JACoP v2.0: Improving the User Experience with Co-localization Studies*, Proc. 2nd Image User Developer Conf (pp. 174–181)
64. Li, Q., Lau, A., Morris, T. J., Guo, L., Fordyce, C. B., and Stanley, E. F. (2004) A syntaxin 1, Galpho, and N-type calcium channel complex at a presynaptic nerve terminal: Analysis by quantitative immunocolocalization. *J. Neurosci.* **24**, 4070–4081
65. Sun, G., Guo, S. M., Teh, C., Korzh, V., Bathe, M., and Wohland, T. (2015) Bayesian model selection applied to the analysis of fluorescence correlation spectroscopy data of fluorescent proteins *in vitro* and *in vivo*. *Anal. Chem.* **87**, 4326–4333
66. Koppel, D. E. (1974) Statistical accuracy in fluorescence correlation spectroscopy. *Phys. Rev. A* **10**, 1938–1945
67. Wohland, T., Rigler, R., and Vogel, H. (2001) The standard deviation in fluorescence correlation spectroscopy. *Biophysical J.* **80**, 2987–2999
68. Widengren, J., Mets, U., and Rigler, R. (1995) Fluorescence correlation spectroscopy of triplet states in solution: A theoretical and experimental study. *J. Phys. Chem.* **99**, 13368–13379
69. Widengren, J., Mets, Ü., and Rigler, R. (1999) Photodynamic properties of green fluorescent proteins investigated by fluorescence correlation spectroscopy. *Chem. Phys.* **250**, 171–186
70. Widengren, J., and Schwille, P. (2000) Characterization of photoinduced isomerization and back-isomerization of the cyanine dye Cy5 by fluorescence correlation spectroscopy. *J. Phys. Chem. A* **104**, 6416–6428
71. Kapusta, P. (2010) *Absolute Diffusion Coefficients: Compilation of Reference Data for FCS Calibration*. Application note, Picoquant GmbH, Berlin, Germany
72. Müller, C. B., Loman, A., Pacheco, V., Koberling, F., Willbold, D., Richter, W., and Enderlein, J. (2008) Precise measurement of diffusion by multi-color dual-focus fluorescence correlation spectroscopy. *EPL (Europhysics Letters)* **83**, 46001
73. Dertinger, T., Pacheco, V., von der Hocht, I., Hartmann, R., Gregor, I., and Enderlein, J. (2007) Two-focus fluorescence correlation spectroscopy: A new tool for accurate and absolute diffusion measurements. *Chemphyschem* **8**, 433–443
74. Bag, N., Sankaran, J., Paul, A., Kraut, R. S., and Wohland, T. (2012) Calibration and limits of camera-based fluorescence correlation spectroscopy: A supported lipid bilayer study. *Chemphyschem* **13**, 2784–2794
75. Sankaran, J., Bag, N., Kraut, R. S., and Wohland, T. (2013) Accuracy and precision in camera-based fluorescence correlation spectroscopy measurements. *Anal. Chem.* **85**, 3948–3954
76. Sankaran, J., Shi, X., Ho, L. Y., Stelzer, E. H. K., and Wohland, T. (2010) ImFCS: A software for Imaging FCS data analysis and visualization. *Opt. Express* **18**, 25468–25481
77. Zahn, R., Liu, A., Luhrs, T., Riek, R., von Schroetter, C., Lopez Garcia, F., Billeter, M., Calzolari, L., Wider, G., and Wuthrich, K. (2000) NMR solution structure of the human prion protein. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 145–150
78. Metzner, C., Kochan, F., and Dangerfield, J. A. (2013) Fluorescence Molecular Painting of Enveloped Viruses. *Mol. Biotechnol.* **53**, 9–18
79. Legler, D. F., Doucey, M. A., Schneider, P., Chapatte, L., Bender, F. C., and Bron, C. (2004) Differential insertion of GPI-anchored GFPs into lipid rafts of live cells. *Faseb J.* **18**, 73–75
80. Riedl, J., Crevenna, A. H., Kessenbrock, K., Yu, J. H., Neukirchen, D., Bista, M., Bradke, F., Jenne, D., Holak, T. A., Werb, Z., Sixt, M., and Wedlich-Soldner, R. (2008) Lifeact: a versatile marker to visualize F-actin. *Nat. Methods* **5**, 605–607